Inspiration of Drug Abuse Surveillance and Warning System of USA to China

Abstract

Abstract: Objective To investigate the drug abuse surveillance and warning system of USA, so as to put forward suggestions for establishing drug abuse risk warning mode in China. Methods Literature, electronic documents and guidelines in drug abuse surveillance and warning system of USA were read and analyzed. Results and Conclusion The drug abuse surveillance and warning system of USA mainly includes drug abuse warning network, national drug early warning system and national drug application and health survey. The main features are relatively complete system, large data collection scope and comprehensive intervention targets. We should strengthen construction of drug abuse surveillance and warning system from the legal construction as soon as possible, and to promote the scientific development of the use of drug abuse monitoring data in China.

Key words: USA, drug abuse, warning, inspiration

CLC Number:

WU Jianru, XIAO Xiao, CHENG Bin, LIU Xiaoyu, WANG Ling, MAO Qiurong. Inspiration of Drug Abuse Surveillance and Warning System of USA to China[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 32-36.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I1/32

References

[1] 刘志民, 吕宪祥. 我国药物滥用监测概述[J]. 中国药物依赖性杂志,2004,13(1):11-17.
[2] 兰教材. 美国1906年纯净食品药品法之由来[J]. 史学月刊,2011,61(2):93-103.
[3] 邹武捷, 满春霞, 杨淑苹, 等. 麻醉药品和精神药品管制研究Ⅱ-美国管制物质的管制历程与现状[J]. 中国药房,2017, 28(1):10-14.
[4] 陈科文, A.Killeya-Jones L. 美国青少年药物滥用和精神障碍共患的流行病学研究进展[J]. 中国药物依赖性杂志,2004,13(4):245-250.
[5] 林晓萍,陈新锦. 美国联邦禁毒执法机构的演变及其影响力探析:从“联邦麻醉品局”到“联邦缉毒署”[J]. 福建警察学院学报,2013, 27(2):22-28.
[6] Javier Porras R G, Hee-Choon Shin, Kenneth A. Rasinski. The Drug Abuse Warning Network (DAWN) Program[J]. Archives of General Paychiatry, 1980, 37(1):106.
[7] Quality CfBHSa. Drug Abuse Warning Network Methodology Report[EB/OL]. (2008-03-04)[2018-06-30].https://www.datafiles.samhsa.gov/study/drug-abuse-warning-network-us-dawn-ns-1997-nid13592.
[8] SAMHDA. National Survey on Drug Use and Health[EB/OL].(2018-02-28)[2018-05-20]. https://www.datafiles.samhsa.gov/study-dataset/national-survey-drug-use-and-health-2016-nsduh-2016-ds0001-nid17185.
[9] 杜存, 刘志民. 刑拘人员药物滥用监测计划概述[J]. 中国药物滥用防治杂志,2008,14(3):155-158.
[10] 连智, 曹家琪, 刘志民. 美国监测未来研究介绍[J]. 中国药物依赖性杂志,1999,8(3):73-74.
[11] 杨玉慧, 许秀丽, 朱珠. 美国阿片类药物滥用及其治理举措概述[J]. 中国药物警戒,2017, 14(12):746-751.
[12] 卢熠. 美国特殊管理药品滥用的监测与干预方式及其启示[J]. 中国药房,2012,23(21):1938-1940.
[13] 美国物质滥用和精神健康服务管理局.安眠药增加急诊风险[J]. 临床合理用药杂志, 2014, 7(9):156.
[14] FDA. 美国FDA警告美沙酮过量引起毒性反应[J]. 中国药物警戒,2007,4(1):55.

[1]	SHEN Chen, ZHOU Xian, LIU Jianping. Database and Evaluation Methods for Chinese Herb-Drug Interactions [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908.
[2]	ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning. Words of Warning and Preventive Measures in Labels of Antidepressants [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
[3]	LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
[4]	ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei. Adverse reaction reports of vancomycin in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
[5]	LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng. Supervision status and research progress of global abuse of opioids [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
[6]	CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng. Management of compound glycyrrhiza oral solution and recommendations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
[7]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[8]	ZHAO Xiaoxiao, XIE Yanming, WANG Lianxin. Clinical applications of elemene emulsion injection in the treatment of lung cancer in the real world based on association rules [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 940-946.
[9]	ZHANG Xiaomeng, LYU Jintao, ZHANG Bing, LIN Zhijian, LIU Rongxue. Risk assessment and pre-warning of injection within Bufonis Venenum in the treatment of liver cancer [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 469-474.
[10]	WANG Dan, WU Chen, REN Jingtian. Risk analysis of dextromethorphan abuse [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1097-1099.
[11]	HUANG Lihong, CHEN Feng. Statistical considerations for real world studies supporting new drug registrations [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 27-31.
[12]	HE Xuan, WANG Xiao, DAI Huizhen, LI Xin, HAN Feng. Usage of New Anti-cancer Drugs in Nanjing from 2018 to 2020 [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 725-730.
[13]	HUANG Zhengkai, LIN Zhijian, WANG Yu, GUO Fanfan, ZHANG Bing. The research on Mechanism and Risk Warning of Melanosis Coli Caused by Emodin [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 753-759.
[14]	WANG Yu, LIN Zhijian, JIANG Zhuoxi, YANG Ting, WANG Xiao, ZHANG Bing. Early Warning of Aconitum Herbs in Breast Cancer Therapy by Bibliometric and Bioinformatics [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 655-662.
[15]	ZOU Lina, LIN Zhijian, ZHANG Xiaomeng, ZHANG Bing, HUANG Zhengkai. Early Warning of Risks of Statins in Atherosclerosis Therapy Based on Bioinformatics [J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 184-189.